Brian McKelligon - 19 Nov 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Reporting relationship: President and CEO, Director
Issuer ticker: AKYA
Reported as of: 19 Nov 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Nov 2024, 17:18:46 UTC
Prior SEC filing: 12 Jun 2024
Next SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian McKelligon

Key filing fact

Brian McKelligon filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 21 Nov 2024.

Key facts

This page summarizes Brian McKelligon's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Nov 2024, 17:18.

Change

Previous filing in this sequence was filed on 12 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKYA transaction

Common Stock

Award

Transaction value: $0
Shares: +218,750
Change %: +97%
Price: $0.000000
Shares after: 443,483
Date: 19 Nov 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock units shall vest as to 50% on the first anniversary of the first day of the month subsequent to the date of grant (the "First Vesting Date") with the remainder vesting as follows: 25% on the date that is three months following the First Vesting Date; 25% on the date that is six months following the First Vesting Date; 25% on the date that is nine months following the First Vesting Date; and 25% on the date that is twelve months following the First Vesting Date.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.